MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202647071870 A) filed by Fortvita Biologics Inc. on June 10, 2026, for Anti-Egfr And -Her3 Bispecific Antibody-Drug Conjugate And Use Thereof.
Inventors include He, Kaijie; Chen, Shi; Zhang, Xiao; and Zhao, Menghui.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: Provided are a bispecific antibody-drug conjugate targeting EGFR and HER3, a pharmaceutical composition containing same, a use thereof in treating or preventing diseases or conditions associated with EGFR and/or HER3 activity, in particular EGFR- and/or HER3-positive tumors, and a use thereof in preparing a medicament for treating or preventing diseases or conditions associated with EGFR and/or HER3 activity, in particular EGFR- and/or HER3-positive tumors.
Disclaimer: Curated by HT Syndication.
